Sangamo Therapeutics, Inc. (SGMOQ)
OTCMKTS · Delayed Price · Currency is USD
0.0500
0.00 (0.00%)
Jun 29, 2026, 3:51 PM EST
Sangamo Therapeutics Revenue
In the year 2025, Sangamo Therapeutics had annual revenue of $39.55M, down -31.57%. Sangamo Therapeutics had revenue of $14.23M in the quarter ending December 31, 2025, with 88.43% growth.
Revenue
39.55M
Revenue Growth
-31.57%
P/S Ratio
0.54
Revenue / Employee
243.36K
Employees
142
Market Cap
18.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 39.55M | -18.25M | -31.57% |
| Dec 31, 2024 | 57.80M | -118.43M | -67.20% |
| Dec 31, 2023 | 176.23M | 64.93M | 58.34% |
| Dec 31, 2022 | 111.30M | 598.00K | 0.54% |
| Dec 31, 2021 | 110.70M | -7.49M | -6.34% |
| Dec 31, 2020 | 118.19M | 15.76M | 15.39% |
| Dec 31, 2019 | 102.43M | 17.98M | 21.29% |
| Dec 31, 2018 | 84.45M | 47.89M | 130.95% |
| Dec 31, 2017 | 36.57M | 17.18M | 88.60% |
| Dec 31, 2016 | 19.39M | -20.15M | -50.96% |
| Dec 31, 2015 | 39.54M | -6.33M | -13.80% |
| Dec 31, 2014 | 45.87M | 21.74M | 90.07% |
| Dec 31, 2013 | 24.13M | 2.48M | 11.44% |
| Dec 31, 2012 | 21.66M | 11.34M | 109.86% |
| Dec 31, 2011 | 10.32M | -10.49M | -50.40% |
| Dec 31, 2010 | 20.81M | -1.38M | -6.23% |
| Dec 31, 2009 | 22.19M | 6.00M | 37.08% |
| Dec 31, 2008 | 16.19M | 7.09M | 77.91% |
| Dec 31, 2007 | 9.10M | 1.21M | 15.38% |
| Dec 31, 2006 | 7.89M | 5.40M | 217.43% |
| Dec 31, 2005 | 2.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kidoz | 18.64M |
| Mercer Bancorp | 7.53M |
| Tennessee Valley Financial Holdings | 6.34M |
| Regency Affiliates | 5.12M |
| CIBL, Inc. | 2.38M |
| Nocopi Technologies | 1.40M |
| ZIVO Bioscience | 209.03K |
| Wytec International | 27.08K |
Sangamo Therapeutics News
- 6 days ago - Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas - GlobeNewsWire
- 21 days ago - Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders - GlobeNewsWire
- 6 weeks ago - Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results - GlobeNewsWire
- 2 months ago - Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) - GlobeNewsWire
- 2 months ago - Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market - GlobeNewsWire
- 3 months ago - Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results - GlobeNewsWire
- 3 months ago - Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call - GlobeNewsWire
- 4 months ago - Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - GlobeNewsWire